The kinds of rodent models in which MOTS-c has been tested since the first paper, and what the pattern of results is

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
After the 2015 paper, MOTS-c was tested by groups in several countries in rodent models that include ovariectomy-induced bone loss, reported from 2016; vascular calcification and atherosclerosis; bacterial infection and sepsis; acute kidney and liver injury; and further obesity and diabetes models. Nearly every report describes a protective or beneficial effect, usually attributed to AMPK activation or reduced inflammation. Most models have been tested once, by one group, with modest animal numbers. The literature is therefore broad and shallow: consistent in direction, thin in replication, and entirely preclinical.

The pattern

A typical report induces a disease state in mice or rats, treats one group with MOTS-c, and finds the treated group less affected on histological, biochemical or functional measures, with AMPK phosphorylation or an inflammatory marker changed in the expected direction. The models span organ systems, which reflects the general appeal of an AMPK activator rather than a specific rationale for each.

Publication bias — positive results being published and null results not — is a recognised concern for literatures of this shape.

How to weigh it

Direction is consistent; magnitude varies; independent replication of any single model is rare. The strongest part of the preclinical record remains the metabolic and exercise work from the originating laboratory, which has been extended across several papers. The disease-model reports add breadth and raise plausibility without establishing any one application.

None of this literature includes humans.

Why it is here

Because a reader searching for MOTS-c and almost any condition will find a mouse paper, and should know what one mouse paper is worth. It describes the shape of a literature and no use of the pack.

MOTS-c is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
MOTS-c Pack40 mgAED 950In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The pattern?

A typical report induces a disease state in mice or rats, treats one group with MOTS-c, and finds the treated group less affected on histological, biochemical or functional measures, with AMPK phosphorylation or an inflammatory marker changed in the expected direction. The models span organ systems, which reflects the general appeal of an AMPK activator rather than a specific rationale for each.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

MOTS-c Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.